Journals / Meme Sağlığı Dergisi / 2008 / Cilt: 4 - Sayı: 1

The evaluaiton of metachronous breast cancer patients

Metakron bilateral meme kanserli hastalarımızın klinik değerlendirilmesi

Pages
38–40
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Patients should be evaluated the risk of BBC carefully at the time of diagnosis and during follow up.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: The incidence of bilateral breast cancer has shown the range from 2% to as high 11%.
📊
Key Findings & Data:METHODS: Medical records of patients who were treated for breast cancer were reviewed during a 5 years period of March 2000 to April 2006.
💡
Conclusion & Impact:Patients should be evaluated the risk of BBC carefully at the time of diagnosis and during follow up.
🔬Design:Review & Systematic Survey
📍Scope:2000 Verileri
⚙️Variables:Yaş dağılımı · Meme neoplazmları · Geriyedönük çalışma

Abstract

OBJECTIVE: The incidence of bilateral breast cancer has shown the range from 2% to as high 11%. Breast cancer patients should follow up against the other side breast cancer risk. METHODS: Medical records of patients who were treated for breast cancer were reviewed during a 5 years period of March 2000 to April 2006. Data of patients found to have bilateral breast cancer (BBC) was analyzed focusing on the demographic information, family history, menstrual status, surgical therapy, staging and histopathological characteristics. RESULTS: Of patients 215 treated for breast cancer 19 (8, 8%) revealed metachronous BBC. The median age was 57, 7 (ranges, 36-77) years. For patients with metachronous breast carcinomas, the median interval between the first and second diagnosis was 8 (ranges, 3-15) years. Six patients with metachronous of them (31,5%) were in postmenopousal, and 13 of them (68, 5%) in premenopousal status. One of metachronous patient revealed positive family history. For metachronous patients, 5, 4, 3, 4 and 3 having stages I, IIA, IIB, IIIA, and IV disease, respectively. The most common type of breast cancer recorded was invasive ductal carcinoma. CONCLUSION: The incidence of BBC reported in this series is similar to the published data. Patients should be evaluated the risk of BBC carefully at the time of diagnosis and during follow up.

Özet

AMAÇ: Kadınlarda meme kanseri, % 2–11 arasında bilateral görülmektedir. Bilateral memede kanser (BMK) gelişme riski nedeniyle unilateral meme kanserli hastaların dikkatli izlenmeleri gerekir. GEREÇ ve YÖNTEM: Hastanemizde, Mart 2000- Nisan 2006 tarihleri arasında meme kanseri tanısı ile ameliyat edilen, iyi dokümente edilmiş 215 hastanın dosyası retrospektif olarak incelendi. Bu hastaların 19’unda (% 8,8) metakron BMK saptandı. Senkron BMK’li 1 hasta çalışma dışı tutuldu. BULGULAR: BMK hastaların yaş ortalaması 57,7 (36-77). Metakron BMK’li hastaların ilk meme kanseri ile karşı meme kanseri arasında geçen süre ortalama 8 (3-15) yıldı. Metakron BMK’li 19 hastanın 6’u (%31,5), postmenapozal, 13’ü (%68,5) premenapozal dönemdeydi. Metakron BMK’li hastaların 1 tanesinde 1. derece akrabasında meme kanseri hikayesi vardı. Tanı sonrası, metakron BMK’li hastaların 5’i Evre I, 4’ü Evre IIA, 3’ü Evre IIB, 4’ü Evre IIIA ve 3’ü Evre IV olarak tespit edildi. Histopatolojik incelemede en sık invaziv duktal karsinom saptandı. SONUÇ: Bu çalışmada da BMK insidansı diğer çalışmalar ile benzer bulundu. BMK gelişme riski nedeniyle gerek tanı anında gerekse tedavi sonrası takipte diğer meme dikkatli olarak incelenmelidir.

🔖

Cite This Article

MENTEŞ, Ö., AKIN, M., ÖZTÜRK, E., BALKAN, M., TUFAN, T. (2008). The evaluaiton of metachronous breast cancer patients. Meme Sağlığı Dergisi, Cilt: 4 - Sayı: 1, 38–40. https://ajindex.com/articles/278256

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Chen Y, Thompson W, Semenciw R, Mao Y. Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarker Prev 1999; 8:855-861. (PMID: 10548312
  2. Robbins GF, Berg JW. Bilateral primary breast cancer: a prospective clinicopathological study. Cancer 1964; 17:1501-1527. (PMID:14239677
  3. Horn PL, Thompson WD. Risk of contralateral breast cancer. Associations with histologic, clinical, and thrapeutic factors. Cancer 1988; 62:412-424. (PMID: 3176526
  4. Janschek E, Kandioler-Eckersberger D, Ludwig C, Koppel S, Wolf B, Taucher S, Rudas M, Gnant M, Jakesz R. Contralateral breast cancer: molecular diff erentiation between metastasis and second primary cancer. Breast Cancer Res Treat 2001; 67:1-8. (PMID: 11518461
  5. Fisher ER, Fisher B, Sass R,Wickerham L. Pathologic Findings from the National Surgical Adjuvant Breast Project (Protocol no.4). XI, Bilateral Breast Cancer. Cancer 1984: 54:3002-3011. (PMID: 6498774
  6. Hartman M, Czene K, Reilly M, Bergh J, Lagiou P, Trihopoulos D, Adami H, Hall P. Genetic implications of bilateral breast cancer: a populationbased cohort study. Lancet Onc 2005; 6:377-382. (PMID: 15925815
  7. Adami HO, Bergstorm R, Hansen J. Age at first primary as a determinant of the incidence of bilateral breast cancer. Cumulative and relative risks in a population-based-case-control study. Cancer 1985; 55:643- 647. (PMID: 3965112
  8. Abdalla I, Thisted RA, Heimann R. The impact of contralateral breast cancer on the outcome of breast cancer patients treated by mastectomy. Cancer Journal 2000; 6-4:p266. (PMID: 11038147
  9. Brenner H, Engelsmann B, Stegmaier C, Ziegler H. Clinical epidemiology of bilateral breast cancer. Cancer 1993; 72:3629-3635. (PMID: 8252478
  10. Nielsen M, Christensen L, Andersen J. Contrlateral cancerous breast lesions in women with clinical invasive breast carcinoma. Cancer 1986; 57:897-903. (PMID: 3002593
  11. Skowronek J, Piotrowski T. Bilateral breast cancer. Neoplasma 2002; 49:49-54, (PMID: 12044060
  12. Mose S, Adamietz IA, Thilmann C, Saran F, Bernhard M, Pahnke R, Bottcher HD. Bilateral breast carcinoma versus unilateral disease. Review of 498 patients. Am J Clin Oncol 1997; 20:541-545. (PMID: 9391536)